Key result
Shenqilixin Formula as an adjunctive therapy to routine treatment significantly improved left ventricular ejection fraction by a mean difference of 4.2% compared to routine treatment alone in patients with chronic heart failure.
Why the study?
Does Shenqilixin Formula (SQLXF) improve cardiac and motor function in patients with chronic heart failure?
Observational (n=135)
No
Does Shenqilixin Formula (SQLXF) improve cardiac and motor function in patients with chronic heart failure?
Mean Difference: 4.2 (95% CI 3–5.4)
Absolute Event Rate: 6.7% vs 2.5%
p-value: p=<.05
Shenqilixin Formula as an adjunctive therapy to routine treatment may improve cardiac and motor function in patients with chronic heart failure.
This study retrospectively evaluated the effectiveness and safety of traditional Chinese medicine Shenqilixin Formula (SQLXF) as an adjunctive intervention for treating patients with chronic heart failure (CHF).This retrospective study included 135 patients with CHF. They were allocated to a treatment group or a control group according to the different treatments they received. Seventy five patients in the treatment group underwent SQLXF plus routine treatment, while 60 subjects in the control group received routine treatment only. The primary outcome was cardiac function. It was measured by the left ventricular end diastolic diameter (LVDD), left ventricular ejection fraction (LVEF), cardiac output (CO), every cardiac output (ECO), and cardiac index (CI). The secondary outcome included motor function. It was measured by the standard 6-MinuteWalk Test (6MWT). In addition, adverse events (AEs) were also recorded.Compared to subjects in the control group, patients in the treatment group revealed greater effectiveness in cardiac function, measured by LVEF (P < .05), CO (P < .05), and ECO (P < .05), and motor function, measured by the 6MWT scale (P < .05). Moreover, no significant differences of AEs were found between the 2 groups.SQLXF as an adjunctive therapy to routine treatment may help to improve both cardiac and motor function in patients with CHF.
No takes yet. Share an insight, caveat, or question.
Sui et al. (2018) conducted an observational in Chronic heart failure (n=135). Shenqilixin Formula (SQLXF) plus routine treatment vs. Routine treatment only was evaluated on Left ventricular ejection fraction (LVEF) change (MD 4.2, 95% CI 3.0-5.4, p=<.05). Shenqilixin Formula as an adjunctive therapy to routine treatment significantly improved left ventricular ejection fraction by a mean difference of 4.2% compared to routine treatment alone in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: